- Home
- EPAM vs INDV Comparison
EPAM vs INDV Comparison
Compare EPAM & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | INDV |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.4B |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EPAM | INDV |
|---|---|---|
| Price | $103.61 | $39.90 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $196.21 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 1.4M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | ★ 1.52 | 0.69 |
| Revenue | ★ $1,450,448,000.00 | $1,239,000,000.00 |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $7.17 | N/A |
| P/E Ratio | $70.32 | ★ $58.12 |
| Revenue Growth | ★ 25.02 | 4.29 |
| 52 Week Low | $73.06 | $19.75 |
| 52 Week High | $222.53 | $42.81 |
Technical Indicators
Market Signals| Indicator | EPAM | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 72.09 | 50.62 |
| Support Level | $89.25 | $38.47 |
| Resistance Level | $109.06 | $41.42 |
| Average True Range (ATR) | 4.53 | 1.34 |
| MACD | 2.39 | -0.13 |
| Stochastic Oscillator | 92.28 | 46.90 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).